Skip to content
DraconiticResearch
Search Sources API
210,049 studies31 sourcesUpdated 33 min ago
Peer-reviewedCC BY-NC 4.0Diabetes Therapy

Combined Semaglutide and Sodium–Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis

  • Shanshan Wang1
  • Bixuan Dong2
  • Zewei Shen2
  1. 1NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin, 300134 China
  2. 2Novo Nordisk (China), Shanghai, China
Read full textPDFDOICite

Abstract

Introduction: Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the use of combination semaglutide–sodium–glucose cotransporter-2 inhibitor (SGLT2i) treatment, glycated hemoglobin (HbA1c) changes, and safety in a subset of SCHOLAR participants.

Methods: Participants from SCHOLAR were included in this post hoc, single-arm analysis if they were prescribed once-weekly subcutaneous semaglutide and had ≥ 1 SGLT2i prescription within 6 months of initiating semaglutide. Participants were grouped according to whether semaglutide use was continuous or not and by baseline HbA1c (≥ 7%). We evaluated the proportion of SCHOLAR participants prescribed combined semaglutide–SGLT2i. Key endpoints were: change in HbA1c from baseline to month 6; proportion of participants achieving a HbA1c level < 7% at month 6; change in lipid profile from baseline to month 6; and safety profile of combined semaglutide–SGLT2i.

Results: A total of 11,361 (42.3%) SCHOLAR participants were treated with combined semaglutide–SGLT2i. Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was − 0.64%-points (− 0.71, − 0.56) (p < 0.0001) for the overall combined semaglutide–SGLT2i group. The greatest change was seen in the continuous semaglutide group with baseline HbA1c ≥ 7% (− 1.20%-points [95% CI − 1.36, − 1.04]). The proportion of participants with HbA1c levels < 7% increased from 37.8% at baseline to 55.1% at month 6 for the overall combined treatment group. There were significant reductions in mean total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and triglycerides (p = 0.0043) as well as a significant increase in high-density lipoprotein cholesterol (p < 0.0001). Gastrointestinal adverse events were most frequent.

Conclusions: Combined semaglutide–SGLT2i treatment was prevalent in this subset of the SCHOLAR population and associated with significant reduction in HbA1c and changes in lipid profile. The safety profile of combined semaglutide–SGLT2i was similar to the overall SCHOLAR population.

Trial Registration Number: NCT06351748.

Related

  1. Diagnostic challenges of masked arginine vasopressin deficiency in neurosarcoidosis complicated by sodium–glucose cotransporter 2 inhibitor use
    JCEM case reportsPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  2. Incidence and predictors of urinary tract infections after sodium-glucose cotransporter 2 inhibitor initiation in older adults hospitalized for heart failure
    Jean-Baptiste Robiaud, Arthur Leroy-Mobeche, Gilles Berrut +6
    Archives of cardiovascular diseasesPeer-reviewedCC BY 4.0Full textEpidemiology & public healthHAL
  3. Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye
    Esra Çokiçli, Murat Kayır, Alp Russel Abbasoğlu +2
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  4. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in an adolescent with type 2 diabetes.
    Natalie Segev, Ryan P Brady, Lawrence Dolan +1
    JCEM case reportsPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismEurope PMC
  5. Sodium-glucose cotransporter 2 inhibitor tofogliflozin ameliorates insulin signaling by improving mitochondrial function in the podocytes in DKD
    Atsuo Nomura, Akira Mima
    Scientific ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ

Cite

BibTeXRIS
BibTeX
@article{wang2026combined,
  title = {{Combined Semaglutide and Sodium–Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis}},
  author = {Shanshan Wang and Bixuan Dong and Zewei Shen},
  journal = {Diabetes Therapy},
  year = {2026},
  month = sep,
  doi = {10.1007/s13300-026-01915-y},
  url = {https://doi.org/10.1007/s13300-026-01915-y},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Combined Semaglutide and Sodium–Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis
AU  - Shanshan Wang
AU  - Bixuan Dong
AU  - Zewei Shen
PY  - 2026
DA  - 2026/09/28
JO  - Diabetes Therapy
DO  - 10.1007/s13300-026-01915-y
UR  - https://doi.org/10.1007/s13300-026-01915-y
AB  - Introduction: Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the use of combination semaglutide–sodium–glucose cotransporter-2 inhibitor (SGLT2i) treatment, glycated hemoglobin (HbA1c) changes, and safety in a subset of SCHOLAR participants.  Methods: Participants from SCHOLAR were included in this post hoc, single-arm analysis if they were prescribed once-weekly subcutaneous semaglutide and had ≥ 1 SGLT2i prescription within 6 months of initiating semaglutide. Participants were grouped according to whether semaglutide use was continuous or not and by baseline HbA1c (≥ 7%). We evaluated the proportion of SCHOLAR participants prescribed combined semaglutide–SGLT2i. Key endpoints were: change in HbA1c from baseline to month 6; proportion of participants achieving a HbA1c level < 7% at month 6; change in lipid profile from baseline to month 6; and safety profile of combined semaglutide–SGLT2i.  Results: A total of 11,361 (42.3%) SCHOLAR participants were treated with combined semaglutide–SGLT2i. Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was − 0.64%-points (− 0.71, − 0.56) (p < 0.0001) for the overall combined semaglutide–SGLT2i group. The greatest change was seen in the continuous semaglutide group with baseline HbA1c ≥ 7% (− 1.20%-points [95% CI − 1.36, − 1.04]). The proportion of participants with HbA1c levels < 7% increased from 37.8% at baseline to 55.1% at month 6 for the overall combined treatment group. There were significant reductions in mean total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and triglycerides (p = 0.0043) as well as a significant increase in high-density lipoprotein cholesterol (p < 0.0001). Gastrointestinal adverse events were most frequent.  Conclusions: Combined semaglutide–SGLT2i treatment was prevalent in this subset of the SCHOLAR population and associated with significant reduction in HbA1c and changes in lipid profile. The safety profile of combined semaglutide–SGLT2i was similar to the overall SCHOLAR population.  Trial Registration Number: NCT06351748.
SN  - 1869-6953
SN  - 1869-6961
ER  -